help button home button Am J Pathol The FASEB Journal
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doroshow, J. H.
Right arrow Articles by Schechter, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doroshow, J. H.
Right arrow Articles by Schechter, J. E.

American Journal of Pathology, Vol 118, 288-297, Copyright © 1985 by American Society for Investigative Pathology


REGULAR ARTICLES

Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity

JH Doroshow, C Tallent and JE Schechter

In this study, the authors examined the effect of the anti-tumor agent Adriamycin, a known cardiotoxin, on mouse heart, diaphragm, and gastrocnemius muscle. Using an established model of Adriamycin cardiac toxicity, they found that 4 days after the intraperitoneal injection of 20 mg/kg of Adriamycin, characteristic heart lesions, including vacuolation of the sarcoplasmic reticulum, interstitial edema, and mitochondrial degeneration, were demonstrated in all treated animals. Furthermore, similar, but much more severe, myocyte damage was demonstrated in the diaphragm; muscle toxicity followed a decreasing gradient of injury from the peritoneal to the thoracic surface of the tissue. On the other hand, treatment with Adriamycin resulted in an increase in the size and number of lipid droplets in the red fibers of the gastrocnemius muscle without any other ultrastructural evidence of drug-induced damage to myocytes. An examination of the pharmacokinetics and metabolism of Adriamycin after intraperitoneal treatment revealed that relative drug levels in muscle (diaphragm much greater than heart much greater than gastrocnemius) paralleled the degree of ultrastructural damage observed. This study indicates that treatment with Adriamycin can produce significant injury to non-cardiac muscle in a fashion that strongly resembles the characteristic pattern of Adriamycin-related damage to the heart, and that the degree of myocyte damage is apparently dependent upon the Adriamycin concentration in the tissue.


This article has been cited by other articles:


Home page
Toxicol PatholHome page
L. Chaiswing, M. P. Cole, D. K. St. Clair, W. Ittarat, L. I. Szweda, and T. D. Oberley
Oxidative Damage Precedes Nitrative Damage in Adriamycin-Induced Cardiac Mitochondrial Injury
Toxicol Pathol, August 1, 2004; 32(5): 536 - 547.
[Abstract] [PDF]


Home page
J. Appl. Physiol.Home page
T. J. Hawke and D. J. Garry
Myogenic satellite cells: physiology to molecular biology
J Appl Physiol, August 1, 2001; 91(2): 534 - 551.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. K. Working, M. S. Newman, T. Sullivan, and J. Yarrington
Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes
J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1128 - 1133.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Society for Investigative Pathology.